Oppenheimer Raises Corvus Pharmaceuticals (NASDAQ:CRVS) Price Target to $14.00

Corvus Pharmaceuticals (NASDAQ:CRVS) had its price target upped by Oppenheimer from $8.00 to $14.00 in a report published on Wednesday,Benzinga reports. The firm currently has an outperform rating on the stock.

Other analysts have also issued reports about the stock. Mizuho upgraded shares of Corvus Pharmaceuticals from a “hold” rating to a “strong-buy” rating in a research note on Tuesday, October 22nd. LADENBURG THALM/SH SH upped their target price on shares of Corvus Pharmaceuticals from $12.00 to $21.00 and gave the stock a “buy” rating in a research note on Monday, September 16th. Finally, StockNews.com cut shares of Corvus Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Thursday, October 31st. One research analyst has rated the stock with a sell rating, three have issued a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus target price of $12.83.

Corvus Pharmaceuticals Trading Down 3.9 %

CRVS stock opened at $8.19 on Wednesday. The business’s fifty day moving average price is $6.83 and its 200 day moving average price is $4.05. Corvus Pharmaceuticals has a 12-month low of $1.30 and a 12-month high of $10.00. The company has a market capitalization of $512.28 million, a PE ratio of -8.81 and a beta of 1.05.

Institutional Inflows and Outflows

Institutional investors have recently added to or reduced their stakes in the company. Vanguard Group Inc. increased its position in shares of Corvus Pharmaceuticals by 10.6% in the 1st quarter. Vanguard Group Inc. now owns 1,493,357 shares of the company’s stock valued at $2,658,000 after purchasing an additional 142,724 shares during the last quarter. Towerview LLC grew its stake in shares of Corvus Pharmaceuticals by 4.6% during the second quarter. Towerview LLC now owns 400,000 shares of the company’s stock worth $728,000 after purchasing an additional 17,500 shares in the last quarter. Samlyn Capital LLC raised its stake in Corvus Pharmaceuticals by 160.7% in the second quarter. Samlyn Capital LLC now owns 6,123,021 shares of the company’s stock valued at $11,144,000 after buying an additional 3,774,658 shares in the last quarter. Marshall Wace LLP purchased a new stake in Corvus Pharmaceuticals during the 2nd quarter worth about $136,000. Finally, Cubist Systematic Strategies LLC acquired a new position in shares of Corvus Pharmaceuticals during the 2nd quarter worth about $44,000. Hedge funds and other institutional investors own 46.64% of the company’s stock.

About Corvus Pharmaceuticals

Corvus Pharmaceuticals, Inc, a clinical stage biopharmaceutical company, focuses on the development and commercialization of immune modulator product candidates to treat solid cancers, T cell lymphomas, autoimmune, allergic, and infectious diseases. Its lead product candidate is soquelitinib (CPI-818), a selective covalent inhibitor of interleukin 2 inducible T cell kinase (ITK), which is in a multi-center Phase 1/1b clinical trial for the treatment of peripheral T cell lymphoma, solid tumors, and atopic dermatitis.